Format

Send to:

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2011 Jan 28;17(4):459-69. doi: 10.3748/wjg.v17.i4.459.

Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Author information

  • 1Department of Nutrition and Health, Nestlé Research Centre, Vers-chez-les-Blanc, Lausanne 26, Switzerland. david.philippe@rdls.nestle.com

Abstract

AIM:

To assess the anti-inflammatory effect of the probiotic Bifidobacterium lactis (B. lactis) in an adoptive transfer model of colitis.

METHODS:

Donor and recipient mice received either B. lactis or bacterial culture medium as control (deMan Rogosa Sharpe) in drinking water for one week prior to transfer of a mix of naive and regulatory T cells until sacrifice.

RESULTS:

All recipient mice developed signs of colonic inflammation, but a significant reduction of weight loss was observed in B. lactis-fed recipient mice compared to control mice. Moreover, a trend toward a diminution of mucosal thickness and attenuated epithelial damage was revealed. Colonic expression of pro-inflammatory and T cell markers was significantly reduced in B. lactis-fed recipient mice compared to controls. Concomitantly, forkhead box protein 3, a marker of regulatory T cells, was significantly up-regulated by B. lactis.

CONCLUSION:

Daily oral administration of B. lactis was able to reduce inflammatory and T cells mediators and to promote regulatory T cells specific markers in a mouse model of colitis.

KEYWORDS:

Adoptive transfer model; Bifidobacterium; Colitis; Inflammation; Mice; Probiotics; Regulatory T cells

PMID:
21274375
[PubMed - indexed for MEDLINE]
PMCID:
PMC3027012
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Write to the Help Desk